10-Q: Rani Therapeutics Secures $75M+ Funding, Advances Oral Drug Delivery

Rani Therapeutics reported reduced net losses and secured over $75 million in new funding and potential milestones, alleviating prior going concern doubts and advancing its oral drug delivery platform.

Summary

• Net loss for the nine months ended September 30, 2025, improved to $31.9 million from $40.9 million in the prior year.
• Research and development expenses decreased by $4.6 million to $15.3 million for the nine months ended September 30, 2025, reflecting cost containment and temporary program pauses.
• General and administrative expenses decreased by $3.8 million to $14.7 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and restricted cash equivalents totaled $4.6 million as of September 30, 2025.
• Subsequent to the reporting period, Rani Therapeutics secured approximately $60.3 million in gross proceeds from a private placement, including a $6.0 million debt conversion.
• A Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. was signed in October 2025, providing a $10.0 million upfront payment and potential milestones up to $175.0 million.
• Additional $4.5 million cash proceeds were received from Series D Warrant exercises in October 2025.
• Preclinical data for RT-114 (bispecific GLP-1/GLP-2 receptor agonist) demonstrated bioequivalence and comparable weight loss to subcutaneous administration, with 111% relative bioavailability.
• Preclinical data for RT-116 (semaglutide via RaniPill HC) showed comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous semaglutide.
• Management believes that recent financing activities have alleviated substantial doubt about the company's ability to continue as a going concern for at least the next twelve months.

Sentiment

Score: 7

Explanation: While the company continues to incur losses and negative operating cash flow, the significant capital raise and major collaboration agreement post-period have alleviated going concern doubts and provide a strong financial runway. Positive preclinical data for key candidates also contribute to a favorable outlook, despite the inherent risks of clinical-stage biotherapeutics development.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $31.9 million from $40.9 million in 2024.
• Substantial new funding secured post-period, including $60.3 million from a private placement and a $10.0 million upfront payment from Chugai.
• Potential for up to $175.0 million in milestone payments and single-digit royalties from the Chugai collaboration.
• Successful preclinical results for RT-114, demonstrating bioequivalence and comparable weight loss to subcutaneous delivery.
• Positive preclinical data for RT-116 (oral semaglutide) showing comparable bioavailability and weight loss to subcutaneous administration.
• Alleviation of prior "going concern" doubt due to recent financing and collaboration agreements.
• Reduced operating expenses, including a $4.6 million decrease in R&D and a $3.8 million decrease in G&A for the nine months ended September 30, 2025.
• Regained compliance with Nasdaq's Minimum Bid Price and Market Value of Listed Securities requirements as of November 4, 2025.

Negatives

• Continued recurring losses since inception, with an accumulated deficit of $122.3 million as of September 30, 2025.
• Negative cash flows from operations of $19.0 million for the nine months ended September 30, 2025.
• Cash and cash equivalents were low at $4.6 million as of September 30, 2025, prior to the subsequent financing events.
• R&D expenses are expected to increase in future periods as programs resume and product development continues.
• The success of the Chugai collaboration and realization of milestone/royalty payments are subject to numerous risks and uncertainties, many outside of Rani's control.

Risks

• The collaboration with Chugai Pharmaceutical Co., Ltd. may not be successful, and Rani Therapeutics may not realize the anticipated benefits, including milestone or royalty payments, if Chugai fails to devote sufficient resources or discontinues development.
• Rani Therapeutics may fail to continue to meet Nasdaq listing standards (e.g., minimum bid price, market value of listed securities), which could lead to delisting and adversely affect stock liquidity and price.
• International trade policies, including tariffs, sanctions, and trade barriers, could adversely affect business, financial condition, and results of operations, particularly due to reliance on third-party suppliers in countries like Korea and China for drug substances and raw materials.
• Increased development costs and extended development timelines due to trade restrictions could place Rani Therapeutics at a competitive disadvantage and reduce investor confidence.
• The company will need to raise substantial additional funds in the future to complete development, clinical trials, regulatory approvals, manufacturing expansion, and commercialization, and there is no guarantee that such funding will be available on acceptable terms or at all.

Future Outlook

Rani Therapeutics expects to continue generating operating losses and negative operating cash flows for the foreseeable future as it develops the RaniPill capsule. The company plans to finance future operations through existing cash and strategic financing opportunities, including equity offerings, collaboration/licensing agreements, or debt. Clinical testing of the RaniPill HC and a Phase 1 trial for RT-114 are expected to initiate by the end of 2025. The company will also seek stockholder approval for common warrants and file registration statements for resale of shares from the recent private placement.

Management Comments

• "We expect to continue to incur losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities."
• "We believe that the proceeds from the closing of the Private Placement, the upfront payment from the Collaboration and License Agreement with Chugai, the proceeds received from Series D Warrant exercises, and the impact of the Debt Conversion provide sufficient capital resources to meet our operating obligations for at least twelve months from the date the condensed consolidated financial statements are issued."
• "Our management believes that the going concern doubt in our 2024 10-K and previous quarterly reports on Form 10-Q has been alleviated."
• "We anticipate the R&D expenses to increase in future periods as we resume these programs and continue to invest in product development."
• "Collectively, these compelling nonclinical results provide a robust rationale for initiating clinical development of RT-114 as a first-in-class oral anti-obesity therapy."

Industry Context

Rani Therapeutics operates in the biotherapeutics and drug delivery industry, focusing on oral administration of biologics and drugs, a significant trend aimed at improving patient convenience and adherence by replacing injections. The development of the RaniPill HC and its successful preclinical results with semaglutide (RT-116) and a GLP-1/GLP-2 dual agonist (RT-114) position the company to potentially disrupt the market for injectable therapies, particularly in high-growth areas like obesity and chronic diseases. The collaboration with Chugai Pharmaceutical Co., Ltd. for a hemophilia antibody further validates Rani's platform technology and its potential application across various therapeutic areas, aligning with industry trends towards strategic partnerships for specialized drug delivery systems.

Related Party Transactions

• Rani Therapeutics has service agreements with InCube Labs, LLC (ICL), an entity wholly-owned by the company's founder and Chairman's family, for personnel and facility occupancy.
• Rani Therapeutics holds a fully paid, exclusive license under certain patents from ICL related to optional features of the device and other scheduled patents for oral delivery of various drugs.
• Rani Therapeutics granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to Rani.
• Certain parties to the Tax Receivable Agreement (TRA), including ICL and its affiliates, are related parties, with potential future payments ranging from $0 to $23.4 million based on tax benefits from Paired Interests exchanges.
• ICL and its affiliates are Continuing LLC Owners with the right to exchange Paired Interests for Class A common stock of Rani Therapeutics Holdings, Inc.

Stakeholder Impact

• Shareholders: Significant dilution from the recent private placement and warrant exercises, but also a substantial capital infusion and a major collaboration that alleviates going concern risk and provides a path for future value creation. Regained Nasdaq compliance is positive for liquidity.
• Employees: Continued investment in R&D and product development, though past cost containment efforts included headcount reduction. Future R&D increases may lead to hiring.
• Customers/Patients: Potential for new, convenient oral drug delivery options for biologics and drugs, reducing reliance on injections.
• Creditors: Debt conversion by the Lender reduces outstanding loan principal and demonstrates confidence, improving the company's financial stability.
• Suppliers: Continued reliance on third-party suppliers for raw materials and APIs, with potential impacts from international trade policies.

Next Steps

• Initiate clinical testing of the RaniPill HC by the end of 2025.
• Initiate a Phase 1 trial for RT-114 by the end of 2025.
• Seek stockholder approval for the issuance of shares underlying the Common Warrants within 75 days following the closing date of the Private Placement.
• File registration statements for the resale of shares and shares underlying warrants from the Private Placement within 15 days of closing, aiming for effectiveness within 45-90 days.
• Continue to develop the RaniPill platform and product candidates.
• Expand manufacturing capabilities and further develop the RaniPill HC device.
• Commercialize any approved product candidates, potentially through partnerships.

Key Dates

Recommendation

Rani Therapeutics has made significant strides in securing crucial financing and a major collaboration, which has successfully addressed the immediate going concern risk. The positive preclinical data for RT-114 and RT-116 are encouraging and validate the RaniPill platform. However, the company remains in a clinical stage with substantial future capital requirements and faces inherent risks associated with drug development, regulatory approvals, and commercialization. The recent capital raise also involved significant dilution. Given the improved financial stability and promising pipeline, but still early stage and execution risks, a 'hold' recommendation is appropriate for investors to monitor clinical progress and the realization of collaboration milestones.

Keywords

Rani Therapeutics, RaniPill, oral drug delivery, biologics, peptides, antibodies, semaglutide, GLP-1, GLP-2, hemophilia, Chugai Pharmaceutical, SEC filing, 10-Q, biotherapeutics, clinical stage, pharmaceutical development, private placement, warrants, debt conversion, preclinical data, Nasdaq listing